Genmab A/S (GMAB) — Estimates & Forecasts
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
| Metric | 2022 | 2023 | 2024 | 2025E | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|---|---|
| Net Income | $5.5B | $4.4B | $7.8B | $6.6B | $8.7B | $11.8B | $13.5B |
| EPS (Diluted) | $8.26 | $6.60 | $12.14 | $10.48 | $13.99 | $19.36 | $22.56 |
| YoY Growth | — | -20.2% | +80.2% | -15.3% | +30.9% | +35.7% | +14.3% |
| Net Margin | 37.6% | 26.4% | 36.4% | 42.1% | 40.2% | 39.1% | 37.7% |
| Metric | 2024A | 2025E | 2026E | 2027E | 2028E |
|---|---|---|---|---|---|
| Revenue | $21.5B | $15.8B | $21.6B | $30.2B | $35.8B |
| Net Income | $7.8B | $6.6B | $8.7B | $11.8B | $13.5B |
| EPS (Diluted) | $12.14 | $10.48 | $13.99 | $19.36 | $22.56 |
| Free Cash Flow | $7.6B | $7.1B | $9.2B | $12.2B | $14.0B |
Treat point estimates cautiously; use wider scenario ranges and position sizing discipline.
Genmab A/S's projected EPS for the next fiscal year is $10.48. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 39/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for Genmab A/S: Bear case $141, Base case $215, and Bull case $413. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
Genmab A/S's projected revenue growth for the next fiscal year is 12.4%, reaching approximately $15.8B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 39/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Contracting margins add uncertainty to forward projections. No forecast model is perfect — always cross-reference with your own analysis.
Genmab A/S's forward operating margin is estimated at 35.5% for the next fiscal year. The margin trend is currently "contracting". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($141) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is above Wall Street consensus with a 724.1% gap. For FY+1, analyst estimates blend with our model at 20% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.